

Hormone-Replacement Therapy and Sleep-Disordered Breathing

Eyal Shahar, M.D., M.P.H.¹
Susan Redline, M.D., M.P.H.²
Terry Young, Ph.D.³
Lori L. Boland, M.P.H.¹
Carol M. Baldwin, RN, Ph.D.⁴
F. Javier Nieto, M.D., Ph.D.³
George T. O'Connor, M.D., M.S.⁵
David M. Rapoport, M.D.⁶
John A. Robbins, M.D.⁷

for the Sleep Heart Health Study Research Group

¹Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, MN

²Division of Clinical Epidemiology, Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, OH

³Department of Population Health Sciences, University of Wisconsin Medical School, Madison, WI

⁴Department of Medicine, Arizona Respiratory Center, University of Arizona Health Sciences Center, Tucson, AZ

⁵Department of Medicine, Boston University School of Medicine, Boston, MA

⁶Department of Medicine, New York University, New York, NY

⁷Department of Medicine, University of California at Davis, Sacramento, CA

Running head: sleep apnea and hormones

Subject Category List: 111

Word Count: Text - 3,868; Abstract - 188

Corresponding Author:

Eyal Shahar, M.D.

Division of Epidemiology

University of Minnesota

1300 South Second Street, Suite 300

Minneapolis, MN 55454

Phone: (612) 624-8231

Fax: (612) 624-0315

E-mail: shahar@epi.umn.edu

This article has an online data supplement, which is accessible from this issue's table of contents at www.atsjournals.org

ABSTRACT

Disordered breathing during sleep is more common among postmenopausal women than among their premenopausal counterparts, possibly due to declining levels of estrogen and progesterone. We examined the relation between the use of replacement hormones and sleep-disordered breathing in a sample of 2,852 free-living women, 50 years of age or older, who participated in the Sleep Heart Health Study. The frequency of apneas and hypopneas per hour of sleep (apnea-hypopnea index) was determined by unattended, single night polysomnography at the participant's home. The prevalence of sleep-disordered breathing (apnea-hypopnea index ≥ 15) among hormone users (61/907) was approximately half the prevalence among nonusers (286/1,945). Multivariable adjustment for known determinants of the disorder, including age, body mass index and neck circumference, has attenuated the association, but only moderately (adjusted odds ratio, 0.55; 95% confidence interval, 0.41 to 0.75). The inverse association between hormone use and sleep-disordered breathing was evident in various subgroups, and was particularly strong among women 50 to 59 years old (adjusted odds ratio, 0.36; 95% confidence interval, 0.21 to 0.60). If the observed associations are causal, hormone-replacement therapy could have a role in preventing or alleviating sleep-disordered breathing.

Key words: sleep apnea, sleep, menopause, estrogen, progesterone

For reasons that are not completely understood, disordered breathing during sleep is more common among postmenopausal women than among their premenopausal counterparts.¹⁻³

Estimates of the prevalence of this condition among women in their sixth or seventh decade of life range from 4 percent to as high as 22 percent,³⁻⁶ depending on the definition used and the study population. Along with other biological sequelae of aging, the transition to the postmenopausal period and the associated hormonal changes might increase the risk of developing sleep-disordered breathing or might exacerbate a pre-existing disorder. These hypotheses are still debated,^{3, 6-9} however, due to paucity of data and the difficulty of distinguishing an effect of the menopause from the effects of other age-related factors.^{10, 11}

If low levels of estrogen and progesterone indeed increase the risk of disordered breathing during sleep, replacement hormones may partially negate this risk and offer preventive and therapeutic benefits to postmenopausal women. To date, two observational studies reported an inverse association between hormone use and sleep-disordered breathing but, in both studies, relatively few women were classified as having the disorder.^{3, 12} Several pilot trials,

the largest of which enrolled 15 women, reported conflicting results.¹³⁻¹⁶ We examined the relation of sleep-disordered breathing to the use of replacement hormones in a sample of nearly 3,000 free-living women.

METHODS

Subjects

The Sleep Heart Health Study is a cohort study of the cardiovascular consequences of sleep-disordered breathing. The study design is described in detail elsewhere.¹⁷ In brief, between November 1995 and January 1998, 6,441 subjects, age 40 years or older, were recruited for the study from population-based cohorts in the U.S. Only three exclusion criteria were specified, reflecting conditions that pose technical difficulties for monitoring sleep physiology or can alter the natural history of sleep-disordered breathing: treatment of sleep apnea with continuous positive airway pressure or an oral device, oxygen treatment at home,

and open tracheostomy. Frequent snoring (three nights per week or more frequently) was somewhat more prevalent in the Sleep Heart Health Study cohort than in the source population (39 percent versus 33 percent) due to self-selection and some intentional over-recruitment of middle-aged habitual snorers. The study protocol was approved by the Institutional Review Boards of the participating institutions. All subjects provided written consent.

Polysomnography

Participants underwent unattended, single night polysomnography at home, using a Compumedics Portable PS-2 System (Abottsville, Australia). On the night of the sleep study, certified technicians placed the sensors on the participant, calibrated the signals, instructed the participant about handling the equipment, and gathered other types of study data. Nine categories of physiological or physical signals were recorded on the sleep monitor: thoracic and abdominal excursions (inductive plethysmography bands); airflow, detected by a nasal-oral thermocouple (Protec, Woodinville, WA); oxyhemoglobin saturation, measured by finger

pulse oximetry (Nonin, Minneapolis, MN); electroencephalogram (C4/A1, C3/A2); bilateral electrooculogram; bipolar submental electromyogram; electrocardiogram (using a bipolar lead); body position (using a mercury gauge sensor); and ambient light (on/off, by a light sensor secured to the recording garment). The sleep studies were stored in real time on PCMCIA cards, down-loaded onto a computer, reviewed at the study site, and then shipped to a central reading center (Case Western Reserve University, Cleveland, OH) where they were reviewed again and scored. Technical details of the hook-up procedure, failure rates, scoring protocols, and quality control procedures are described elsewhere.¹⁸

We defined an apnea as a complete, or nearly complete, cessation of airflow (amplitude of the thermocouple signal smaller than 25 percent of the baseline amplitude) for 10 seconds or longer. A hypopnea was defined as a decrease in the amplitude of a measure of flow (thermocouple signal) or a measure of volume (thoracic or abdominal inductance band signals) to amplitude smaller than 70 percent of the baseline amplitude for 10 seconds or longer. For this analysis, we considered only apneas and hypopneas that were associated with oxyhemoglobin desaturation of four percent or greater relative to the baseline.

We computed the apnea-hypopnea index, a widely used measure of sleep-disordered breathing, by dividing the total number of apneas and hypopneas (respiratory events) by the total sleep time in hours. To the extent possible, we distinguished obstructive events from central events; however, the contribution of the latter to the apnea-hypopnea index was small. Only two percent of the participants had an average of central events per hour of sleep that was greater than one. The inter-scorer reliability for the apnea-hypopnea index was high (intraclass correlation coefficient, 0.99).¹⁹ Sleep stages were identified according to the guidelines of Rechtschaffen and Kales.²⁰ Sleep stages 3 and 4 (slow-wave sleep) were combined.

Use of Replacement Hormones

Participants were asked to gather all the medications they had taken during the two-weeks before the night of the study. The name and the dose of each medication were transcribed by the study technicians and matched with a computerized database of prescription and non-

prescription medications.²¹ The duration of medication use was not recorded. We defined hormone users as users of estrogen or users of estrogen and progesterone. Most hormone users (82%) were taking Premarin.

Other Measurements and Variables

Information about daytime sleepiness, snoring, and other sleep-related items was obtained from a self-completed questionnaire, which was provided to the participant during the recruitment contacts and was filled out before the night of the sleep study. Daytime sleepiness was assessed by a direct question —“how often do you feel excessively sleepy during the day?” — and by a summary score on the Epworth sleepiness questionnaire.²² The higher the Epworth questionnaire score, the greater the magnitude of reported daytime sleepiness. We defined five categories of snoring status: habitual (6 to 7 night per week); frequent (3 to 5 nights per week); light (up to 2 nights per week); no snoring; and unknown.

Medical history was recorded on the night of the study using an interviewer-administered questionnaire. Body weight was measured in kilograms on a portable digital scale. Neck circumference was measured in centimeters at the level of the laryngeal prominence,²³ and rounded to the nearest 0.5 of an integer. Since the participants were recruited from ongoing cohort studies, the parent study provided the values of the following variables: date of birth, race, height, waist circumference, and hip circumference. Race was classified as Caucasian, African American, American Indian, or “other” (primarily Hispanic origin). We computed the body-mass index (the weight in kilograms divided by the square of the height in meters) and the waist-to-hip ratio.

Statistical Analysis

A total of 3,399 women participated in the study. Because menopausal status was not recorded on the night of the sleep study, we restricted the sample to women who were 50 years of age or older (N=2,994), assuming that most women in this age range were postmenopausal and a small proportion were perimenopausal. As shown later, setting the

cutoff for age even higher (55 years) had no material effect on the results. We excluded 12 women who were taking progesterone but not estrogen, 4 women with missing information on hormone use, and 126 women with missing data on key covariates. The final sample included 2,852 observations. Analysis of sleep stages was based on a similar sample size (N=2,854) but a slightly different sample due to different criteria of acceptable polysomnograms for the scoring of sleep stages.

Characteristics of hormone users and nonusers were compared by computing mean values, standard deviations, and percentiles (of continuous variables) or proportions (for categorical variables). In addition, we compared the distribution of the apnea-hypopnea index in hormone users and nonusers by displaying the proportion of women from each group in deciles of the index distribution in the entire sample (users and nonusers combined).

The distribution of the apnea-hypopnea index was skewed, but log transformation of the index (adding 0.1 to allow transformation of a zero value) generated an approximately

normal distribution. Adjusted mean values of the log-transformed apnea-hypopnea index among hormone users and nonusers were estimated from multiple linear regression models (analysis of covariance) that included known determinants of sleep-disordered breathing: age, race, body-mass index, waist-to-hip ratio, and neck circumference. Adjusted geometric means (often approximating median values) were computed by back-transformation (taking the anti-logarithm). Similarly, back transformation of the difference between the mean of log-transformed apnea-hypopnea index among hormone users and nonusers has yielded the ratio of the geometric means.²⁴ Confidence intervals for the geometric mean ratio were computed by back transforming the 95 percent confidence bounds for the mean difference.²⁴

To further examine the association of hormone use with sleep-disordered breathing, we fit multivariable logistic regression models, dichotomizing the apnea-hypopnea index at a value of 15 for our principal analysis and at a value of 20 for sensitivity analysis. To examine the relation of hormone use to nocturnal hypoxemia, an important consequence of sleep-disordered breathing, we computed the percent of sleep time during which oxyhemoglobin

saturation declined below 90 percent, used two cutoff values — five percent and ten percent of the total sleep time — and fit multivariable logistic regression models.

The association of hormone use with sleep stages was examined in multiple linear regression models. Because of considerable skewness of the distributions, the proportions of sleep time (P) in stage 1, and stages 3 and 4 combined were transformed according to the formula $-\log(-\log(P+0.001))$ with back transformation of the least-square estimates. The distributions of the proportion of sleep time in stage 2 and REM sleep were approximately normal.

RESULTS

A total of 907 women (32%) were using replacement hormones, of whom 525 were taking estrogen alone and 382 were taking estrogen and progesterone. The frequency of hormone use declined across ascending age groups, from 46 percent among women 50 to 59 years old

to 33 percent among women 60 to 69 years old to 18 percent among women ≥ 70 years old.

Compared to women who did not use hormones, hormone users were more likely to be of

Caucasian descent than African American or American Indian descent, and tended to be

thinner (1.1 kg/m² mean difference of body mass index) and healthier (See Table E1 in the

online data supplement). A larger proportion of hormone users than nonusers reported

feeling excessively sleepy during the day and often taking a medication for sleep. Although

other sleep-related symptoms (“not getting enough sleep” and “waking up during the night”)

were as prevalent among hormone users as among nonusers, the former group scored slightly

higher on the Epworth sleepiness scale. A similar proportion of women in each group

reported frequent or habitual snoring (25 percent of users and 23 percent of nonusers), but

snoring status remained unknown for a greater proportion of nonusers than users. The

distribution of both the apnea-hypopnea index and the hypoxemia index among users of

replacement hormones was shifted to the left as compared with the distribution of these

variables among nonusers (Table E1 and Figure 1).

Table 1 contrasts the adjusted geometric mean of the apnea-hypopnea index among hormone users with the corresponding mean among nonusers, in the entire sample and in subgroups of women. (See a complete version of this table - Table E2 - in the online data supplement.) In most of the models, the adjusted geometric mean among users of hormones was 25 to 30 percent lower than among nonusers and the majority of the estimates were fairly precise (upper-to-lower 95 percent confidence bound ratio smaller than 1.5). The inverse association between use of replacement hormones and the apnea-hypopnea index was attenuated with aging (test for interaction: $P=0.03$) but was very similar in women classified as normal weight (body-mass index $< 25 \text{ kg/m}^2$), overweight ($25 \leq \text{body-mass index} \leq 30 \text{ kg/m}^2$), and obese (body-mass index $> 30 \text{ kg/m}^2$). Likewise, the point estimates did not vary much across subgroups defined by self-reported general health or after the exclusion of women with several major clinical conditions (Table E2). In most cases, departure from the “typical” geometric mean ratio in this sample (ranging from 0.68 to 0.76 in most subgroups) was related to small-size strata. The association of hormone use with the apnea-hypopnea index was similar for users of estrogen alone and users of estrogen and progesterone (geometric

mean ratio of 0.71 and 0.75, respectively). We found nearly identical associations of hormone use with REM-related apnea-hypopnea index and non-REM related apnea-hypopnea index. Of note, the estimates were derived from linear regression models that fit the data reasonably well (all $R^2 > 0.19$).

As shown in Table 2, a total of 347 women (12 percent of the sample) had an apnea-hypopnea index ≥ 15 . Of these, 61 women were taking hormones and 286 were not. The prevalence of sleep-disordered breathing among hormone users (61/907) was approximately half the prevalence among nonusers (286/1,945) and adjustment for known determinants of sleep-disordered breathing only moderately attenuated the magnitude of this association (adjusted odds ratio 0.55; 95 percent confidence interval, 0.41 to 0.75). Similar to the geometric mean ratio, the estimated odds ratio did not vary significantly across several subgroups and participants' characteristics except age (test for interaction: $P=0.013$). The inverse relation between hormone use and sleep-disordered breathing was particularly strong among women 50 to 59 years old (odds ratio, 0.36; 95 percent confidence interval 0.21 to

0.60); was weaker, but still strong, among 60 to 69 year olds (odds ratio, 0.55; 95 percent confidence interval, 0.32 to 0.95); and was weakest among the oldest age group (odds ratio, 0.86; 95 percent confidence interval 0.52 to 1.43). In most of the models, the use of replacement hormones was associated with approximately 40 to 50 percent lower odds of having an apnea-hypopnea index ≥ 15 after adjustment for determinants of sleep-disordered breathing. (See Table E3 – online data supplement.) The associations were similar, and in some cases stronger, when the apnea-hypopnea index was dichotomized at 20.

Table 3 shows the adjusted odds ratios for experiencing hypoxemia (oxyhemoglobin saturation < 90 percent) during 5 percent or more of total sleep time (359 women) and during 10 percent or more of total sleep time (198 women). The results are largely consistent with those for the apnea-hypopnea index, especially among women 50 to 70 years old, but the estimates varied across the three strata of body mass index and the two case definitions.

Modeling the odds of a more restrictive case definition (desaturation during 10 percent or more of total sleep time) often yielded stronger associations. There was some suggestion of a

stronger inverse relation of the hypoxemia indices with use of estrogen and progesterone than with use of estrogen alone.

The distribution of sleep stages among hormone users tended to be similar to the distribution among nonusers or somewhat worse (Table 4). Users of replacement hormone spent a slightly greater percentage of their sleep time in stages 1 and 2 and a smaller percentage in deep, restorative sleep (stages 3-4). However, the mean percentage of sleep time in REM stage was slightly greater among users of replacement hormones than among nonusers. In two cases (stage 2 and stages 3-4), there was strong statistical evidence against the null hypothesis of no association, but the estimated differences between the two groups were small. It should be noted that point estimates and related statistics were derived from regression models that did not account for much of the variance of the proportion of sleep time in any sleep stage ($R^2 \leq 0.07$). We repeated the analyses of sleep stages using only 2,762 observations nested in the sample that was used for analyses involving the apnea-hypopnea index. The results were nearly identical (data not shown).

DISCUSSION

We found an inverse association between use of replacement hormones in the postmenopausal period and sleep-disordered breathing. The association was consistent across various subgroups and was particularly strong among women 50 to 70 years old. To place our results in perspective, we compared the association of sleep-disordered breathing with hormone use to its association with body-mass index, a key determinant of the disorder.

In our main multivariable model of sleep-disordered breathing, the estimated odds ratio for hormone users as compared with nonusers (0.55) corresponded to the predicted effect of reducing body-mass index by 6.8 kg/m^2 . Similarly, the estimated odds ratio for hormone use among women in their sixth decade of life (0.36) corresponded to the predicted effect of reducing body-mass index by 11.6 kg/m^2 . If the observed associations are causal, hormone replacement therapy could have a significant role in the prevention or treatment of sleep-disordered breathing in postmenopausal women.

Although the magnitude of confounding appeared to have been moderate, residual confounding by one of the covariates is a possible explanation for our findings. Body-fat distribution and body-mass index were the principal confounders in this sample, presumably through the following mechanism: Because thinner women might be more likely to experience menopausal symptoms^{25, 26} and are perhaps more health conscious than heavier women, the former are more likely to take replacement hormones and are also expected to experience little or milder sleep-disordered breathing, regardless of any effect of replacement hormones. Three counterpoints should be considered, however. First, the inverse association between hormone use and sleep-disordered breathing was evident within three strata of body-mass-index, with further adjustment for body-mass index, neck circumference, and other covariates within each stratum. Second, our findings were consistent across most strata of self-reported health including the group of women who rated their general health as “very good” or “excellent”. This group was presumably fairly homogenous with respect to their health status. Third, the magnitude of confounding by the modeled covariates was moderate;

most of the associations remained relatively strong after adjustment. Of course, we cannot exclude the possibility of confounding by an unknown, strong determinant of sleep-disordered breathing.

Use of replacement hormones was not uniformly associated with better sleep parameters, indicating, perhaps, that it was not a general marker of favorable sleep quality. In fact, hormone users were more likely than nonusers to report daytime sleepiness, to use a medication for sleep, and to have slightly worse sleep architecture (a smaller proportion of stages 3 and 4). Although subjective sleep problems and menopause-related sleep disruption could have led some women to seek medical attention and be treated with replacement hormones, this sequence of events is not expected to account for an inverse association between use of replacement hormones and sleep-disordered breathing. If at all, women who started taking hormones because they had perceived difficulty with sleep should have been more likely — not less likely — to suffer from sleep-disordered breathing.

A handful of small trials tested the effect of estrogen, progesterone, or both on sleep-disordered breathing in postmenopausal women,^{13-16, 27} three of which reported a moderate to strong beneficial effect.^{13, 14, 16} Inference from these trials is severely constrained, however, by methodological limitations such as a small sample size,^{13-16, 27} lack of a control group or a control period,^{15, 16} short duration of treatment,^{13, 15, 16, 27} use of progesterone alone,²⁷ and non-blinded treatment assignment.¹⁴⁻¹⁶ To our knowledge, only two observational studies have examined the issue. Bixler and colleagues compared the odds of prevalent sleep-disordered breathing (obstructive apnea-hypopnea index ≥ 15) among postmenopausal women and premenopausal women.³ Postmenopausal women who were not using replacement hormones had much greater odds of sleep-disordered breathing than premenopausal women, but the odds of sleep-disordered breathing were very similar in postmenopausal hormone users and premenopausal women. The study estimates, however, were based on a small number of women with sleep-disordered breathing (fewer than 30). Young and colleagues reported similar preliminary results from a subset of the Wisconsin Sleep Cohort study.¹²

Several postulated mechanisms could explain a causal connection between sleep-disordered breathing and low levels of circulating estrogen and progesterone, thereby explaining a putative benefit of hormone-replacement therapy.

Sleep-disordered breathing of the obstructive type is positively associated with indicators of central adiposity, and is particularly related to the amount of fat in the neck^{28, 29} and around the palatopharyngeal airspace,³⁰⁻³³ the typical site of airway obstruction. Though speculative, menopause-related changes in body fat distribution, from gynoid phenotype to android features,³⁴⁻³⁶ may also include deposition of fat around the upper airway. The effect of the menopause on body fat distribution is ascribed to declining levels of estrogen and progesterone, and appears to be negated or attenuated by use of replacement hormones.³⁷⁻⁴⁰ If replacement hormones indeed protect against sleep-disordered breathing through this mechanism, our estimates of the effect size may be conservative because adjustment for neck circumference could have embedded some over-adjustment.

Upper airway patency during sleep is determined, in part, by the tonus of pharyngeal dilator muscles. Popovic and White found that the activity of the genioglossus muscle during wakefulness was lower in postmenopausal women than in premenopausal women, yet significantly increased in eight postmenopausal women following two-week treatment with conventional doses of replacement hormones.⁴¹ Progesterone, and possibly estrogen, also play a role in the regulation of the ventilatory drive, raising the hypoxic ventilatory response⁴² and stimulating ventilation in conditions of hypoventilation.⁴³ Declining levels of these hormones might predispose some women to sleep-disordered breathing by lowering the ventilatory drive to the upper airway, which could lead to imbalance between forces that jeopardize upper airway patency and counteracting forces.⁴⁴ Of the two hormones, progesterone is the principal stimulant of ventilation, but several studies point to synergistic effects of both hormones,^{42, 45, 46} perhaps because estrogen induces the formation of progesterone receptors.⁴⁷ A role for progesterone in sleep-disordered breathing among postmenopausal women is supported, to some extent, by our finding of a stronger inverse

association of indices of hypoxemia with combined use of estrogen and progesterone than with use of estrogen alone.

Finally, declining levels of estrogen and progesterone may contribute to non-synchronized CNS activation of inspiratory muscles and pharyngeal dilator muscles – a possible mechanism of upper airway obstruction.⁴⁴ This hypothesis gain support from physical proximity of CNS centers that regulate sleep physiology and centers that regulate body temperature,^{48, 49} both of which appear to be sensitive to estrogen levels and brain hypoestrogenism.⁴⁸ Estrogen and progesterone can also modulate the levels or activity of certain neurotransmitters;^{47, 50} some of these factors may play a role in the regulation of sleep.⁵¹

Several limitations of our study should be acknowledged. We did not have information on menopausal status at the time of the sleep study and, therefore, could not assess the effect of the menopause itself on sleep-disordered breathing nor verify that all of the women in the

sample were postmenopausal. Nonetheless, if the sample included premenopausal women, they were likely younger women who were not taking hormones. And since younger women are expected to have a milder degree of sleep-disordered breathing, the inclusion of premenopausal women in the group of nonusers is expected to attenuate the contrast between hormone users and nonusers and lead to underestimation of the true association between hormone use and sleep-disordered breathing.

We could not draw inference on the relation of hormone-replacement therapy to snoring, a common manifestation of sleep-disordered breathing, because the proportion of women who did not know whether they snored differed between hormone users and nonusers. Since information on the duration of hormone use was not available, we could not shed light on the time it might take to observe an effect, or about the effect of starting to take hormones at various ages. Data from small trials and postulated causal pathways suggest that the effect of replacement hormones, if any, should be evident after several weeks of treatment but a much longer treatment period might be required to achieve maximal benefit via a mechanism such

as redistribution of parapharyngeal fat. Finally, the cross-sectional nature of the sample precludes clear inference about the relation of hormone use to self-reported sleep problems and sleep architecture because cross-sectional associations may reflect two historical effects: a tendency to prescribe replacement hormones to women who report disrupted sleep and a favorable effect, if any, of hormone use on sleep quality.

In summary, accumulating data suggest that replacement hormones could prevent or alleviate sleep-disordered breathing among postmenopausal women. In light of known consequences of symptomatic sleep apnea,^{52, 53} and possible consequences of mild-to-moderate sleep-disordered breathing,⁵⁴⁻⁵⁶ additional tests of this hypothesis are warranted.

Conflict of Interest:

None

ACKNOWLEDGMENTS

This work was supported by National Heart, Lung and Blood Institute cooperative agreements UO1HL53940 (University of Washington), UO1HL53941 (Boston University), UO1HL53938 (University of Arizona), UO1HL53916 (University of California, Davis), UO1HL53934 (University of Minnesota), UO1HL53931 (New York University), UO1HL53937 (Johns Hopkins University), UO1HL63463 (Case Western Reserve University), and UO1HL63429 (Missouri Breaks Research).

The Sleep Heart Health Study (SHHS) acknowledges the Atherosclerosis Risk in Communities Study (ARIC), the Cardiovascular Health Study (CHS), the Framingham Heart

Study (FHS), the Cornell/Mt. Sinai Worksite and Hypertension Studies, the Strong Heart Study (SHS), the Tucson Epidemiologic Study of Airways Obstructive Diseases (TES) and the Tucson Health and Environment Study (H&E) for facilitating the recruitment of members of their cohorts and for permitting data acquired by them to be used in the study.

We are particularly grateful to members of these cohorts who agreed to participate in SHHS as well. We further acknowledge the investigators and staff who have contributed to the design and conduct of the study. A list of SHHS investigators, staff, and participating institutions is available on the SHHS website, www.jhsph.edu/shhs.

The opinions expressed in the paper are those of the authors and do not necessarily reflect the views of the Indian Health Services.

References:

1. Block AJ, Boysen PG, Wynne JW, Hunt LA. Sleep apnea, hypopnea and oxygen desaturation in normal subjects. A strong male predominance. *N Engl J Med* 1979; 300:513-7.
2. Redline S, Kump K, Tishler PV, Browner I, Ferrette V. Gender differences in sleep disordered breathing in a community-based sample. *Am J Respir Crit Care Med* 1994; 149:722-6.
3. Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. *Am J Respir Crit Care Med* 2001; 163:608-13.
4. Ancoli-Israel S, Kripke DF, Klauber MR, Mason WJ, Fell R, Kaplan O. Sleep-disordered breathing in community-dwelling elderly. *Sleep* 1991; 14:486-95.
5. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993; 328:1230-5.

6. Kripke DF, Ancoli-Israel S, Klauber MR, Wingard DL, Mason WJ, Mullaney DJ. Prevalence of sleep-disordered breathing in ages 40-64 years: a population-based survey. *Sleep* 1997; 20:65-76.
7. Leech JA, Onal E, Dulberg C, Lopata MA. A comparison of men and women with occlusive sleep apnea syndrome. *Chest* 1988; 94:983-8.
8. Bresnitz EA, Goldberg R, Kosinski RM. Epidemiology of obstructive sleep apnea. *Epidemiol Rev* 1994; 16:210-27.
9. Carskadon MA, Bearpark HM, Sharkey KM, et al. Effects of menopause and nasal occlusion on breathing during sleep. *Am J Respir Crit Care Med* 1997; 155:205-10.
10. Moe KE. Reproductive hormones, aging, and sleep. *Semin Reprod Endocrinol* 1999; 17:339-48.
11. Young T. Menopause, hormone replacement therapy, and sleep-disordered breathing: are we ready for the heat? *Am J Respir Crit Care Med* 2001; 163:597-8.
12. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. *Am J Respir Crit Care Med* 2002; 165:1217-1239.

13. Pickett CK, Regensteiner JG, Woodard WD, Hagerman DD, Weil JV, Moore LG.
Progesterin and estrogen reduce sleep-disordered breathing in postmenopausal women.
J Appl Physiol 1989; 66:1656-61.
14. Franklin K, Lundgren R, Rabben T. Sleep apnoea syndrome treated with oestradiol
and cyclic medroxyprogesterone. *Lancet* 1991; 338:251-2.
15. Cistulli PA, Barnes DJ, Grunstein RR, Sullivan CE. Effect of short-term hormone
replacement in the treatment of obstructive sleep apnoea in postmenopausal women.
Thorax 1994; 49:699-702.
16. Keefe DL, Watson R, Naftolin F. Hormone replacement therapy may alleviate sleep
apnea in menopausal women: a pilot study. *Menopause* 1999; 6:196-200.
17. Quan SF, Howard BV, Iber C, et al. The Sleep Heart Health Study: design, rationale,
and methods. *Sleep* 1997; 20:1077-85.
18. Redline S, Sanders MH, Lind BK, et al. Methods for obtaining and analyzing
unattended polysomnography data for a multicenter study. Sleep Heart Health
Research Group. *Sleep* 1998; 21:759-67.

19. Whitney CW, Gottlieb DJ, Redline S, et al. Reliability of scoring respiratory disturbance indices and sleep staging. *Sleep* 1998; 21:749-57.
20. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington D.C.: U.S. Government Printing Office, 1968:(NIH Publication No. 204).
21. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. *J Clin Epidemiol* 1992; 45:683-92.
22. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991; 14:540-5.
23. Callaway CW, Chumlea WC, Bouchard C, et a. Circumferences. In: Lohman TG, Roche AF, Martorell R, eds. *Anthropometric Standardization Reference Manual*. Champaign, Ill: Human Kinetics, 1988:41-42.

24. Bland JM, Altman DG. The use of transformation when comparing two means. *Bmj* 1996; 312:1153.
25. Sternfeld B, Quesenberry CP, Jr., Husson G. Habitual physical activity and menopausal symptoms: a case-control study. *J Womens Health* 1999; 8:115-23.
26. Schwingl PJ, Hulka BS, Harlow SD. Risk factors for menopausal hot flashes. *Obstet Gynecol* 1994; 84:29-34.
27. Block AJ, Wynne JW, Boysen PG, Lindsey S, Martin C, Cantor B. Menopause, medroxyprogesterone and breathing during sleep. *Am J Med* 1981; 70:506-10.
28. Millman RP, Carlisle CC, McGarvey ST, Eveloff SE, Levinson PD. Body fat distribution and sleep apnea severity in women. *Chest* 1995; 107:362-6.
29. Deegan PC, McNicholas WT. Predictive value of clinical features for the obstructive sleep apnoea syndrome. *Eur Respir J* 1996; 9:117-24.
30. Horner RL, Mohiaddin RH, Lowell DG, et al. Sites and sizes of fat deposits around the pharynx in obese patients with obstructive sleep apnoea and weight matched controls. *Eur Respir J* 1989; 2:613-22.

31. Shepard JWJ, Gefter WB, Guilleminault C, et al. Evaluation of the upper airway in patients with obstructive sleep apnea. *Sleep* 1991; 14:361-71.
32. Shelton KE, Woodson H, Gay S, Suratt PM. Pharyngeal fat in obstructive sleep apnea. *Am Rev Respir Dis* 1993; 148:462-6.
33. Mortimore IL, Marshall I, Wraith PK, Sellar RJ, Douglas NJ. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. *Am J Respir Crit Care Med* 1998; 157:280-3.
34. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. *Am J Clin Nutr* 1992; 55:950-4.
35. Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: a controlled longitudinal study. *Ann Intern Med* 1995; 123:673-5.
36. Tremollieres FA, Pouilles JM, Ribot CA. Relative influence of age and menopause on total and regional body composition changes in postmenopausal women. *Am J Obstet Gynecol* 1996; 175:1594-600.

37. Haarbo J, Marslew U, Gotfredsen A, Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. *Metabolism* 1991; 40:1323-6.
38. Reubinoff BE, Wurtman J, Rojansky N, et al. Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study. *Fertil Steril* 1995; 64:963-8.
39. Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. *J Clin Endocrinol Metab* 1997; 82:1549-56.
40. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. *Maturitas* 2001; 39:125-32.

41. Popovic RM, White DP. Upper airway muscle activity in normal women: influence of hormonal status. *J Appl Physiol* 1998; 84:1055-62.
42. Regensteiner JG, Woodard WD, Hagerman DD, et al. Combined effects of female hormones and metabolic rate on ventilatory drives in women. *J Appl Physiol* 1989; 66:808-13.
43. Robinson RW, Zwillich CW. The effects of drugs on breathing during sleep. *Clin Chest Med* 1985; 6:603-14.
44. Hudgel DW, Suratt PM. The Human Airway During Sleep. In: Saunders NA, Sullivan CE, eds. *Sleep and Breathing*. New York: Marcel Dekker, 1994:191-208.
45. Brodeur P, Mockus M, McCullough R, Moore LG. Progesterone receptors and ventilatory stimulation by progestin. *J Appl Physiol* 1986; 60:590-5.
46. Hannhart B, Pickett CK, Moore LG. Effects of estrogen and progesterone on carotid body neural output responsiveness to hypoxia. *J Appl Physiol* 1990; 68:1909-16.

47. Vliet EL, Davis VL. New perspectives on the relationship of hormone changes to affective disorders in the perimenopause. *NAACOGS Clin Issu Perinat Womens Health Nurs* 1991; 2:453-71.
48. Arpels JC. The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. *J Reprod Med* 1996; 41:633-9.
49. McGinty D, Szymusiak R. Neurobiology of sleep. In: Saunders NA, Sullivan CE, eds. *Sleep and Breathing*. Vol. 71. New York, NY: Marcel Dekker, 1994:1-26.
50. Manber R, Armitage R. Sex, steroids, and sleep: a review. *Sleep* 1999; 22:540-55.
51. Krueger JM, Obal F, Jr. Sleep factors. In: Saunders NA, Sullivan CE, eds. *Sleep and Breathing*. New York, NY: Marcel Dekker, 1994:79-112.
52. Phillipson EA. Sleep apnea: a major public health problem. *N Engl J Med* 1993; 328:1271-3.
53. Drazen JM. Sleep apnea syndrome. *N Engl J Med* 2002; 346:390.

54. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. *Jama* 2000; 283:1829-36.
55. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med* 2000; 342:1378-84.
56. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. *Am J Respir Crit Care Med* 2001; 163:19-25.

Figure 1: Distribution of the apnea-hypopnea index according to use of replacement

hormones. Deciles correspond to the distribution of the index in the entire sample

(users and nonusers combined)

TABLE 1. Relation of Hormone-Replacement Therapy to the Apnea-Hypopnea Index*

CHARACTERISTIC		N	ADJUSTED LOG (APNEA-HYPOPNEA INDEX)	ADJUSTED GEOMETRIC MEAN	ADJUSTED GEOMETRIC MEAN RATIO	95% CONFIDENCE INTERVAL
ALL WOMEN						
	Users	907	0.83 ± 0.04	2.3	0.73	0.65 - 0.81
	Nonusers	1945	1.15 ± 0.03	3.2		
AGE GROUP (Years)						
50-59	Users	430	0.85 ± 0.09	2.3	0.66	0.55 - 0.78
	Nonusers	498	1.27 ± 0.09	3.5		
60-69	Users	292	0.88 ± 0.08	2.4	0.71	0.59 - 0.85
	Nonusers	593	1.23 ± 0.05	3.4		
≥ 70	Users	185	0.86 ± 0.12	2.4	0.87	0.70 - 1.06
	Nonusers	854	1.00 ± 0.09	2.7		
BODY-MASS INDEX (kg/m ²)						
< 25	Users	292	0.81 ± 0.09	2.2	0.76	0.63 - 0.91
	Nonusers	530	1.09 ± 0.08	3.0		
25-30	Users	345	0.76 ± 0.07	2.1	0.73	0.61 - 0.86
	Nonusers	696	1.08 ± 0.05	3.0		
> 30	Users	270	0.92 ± 0.09	2.5	0.70	0.58 - 0.84
	Nonusers	719	1.28 ± 0.07	3.6		
TYPE OF HORMONE						
Estrogen only	Users	525	0.81 ± 0.06	2.3	0.71	0.63 - 0.81
	Nonusers	1945	1.15 ± 0.03	3.2		
Estrogen and Progesterone	Users	382	0.86 ± 0.07	2.4	0.75	0.64 - 0.87
	Nonusers	1945	1.15 ± 0.03	3.2		

* Estimates were derived from linear regression models that included age, body mass index, waist-to-hip ratio, neck circumference, and race group as covariates. All covariates, except race group, were entered as continuous variables. To minimize residual confounding, age (continuous) and body mass index (continuous) were also included in models that examined the relation of hormone-replacement therapy to sleep-disordered breathing within categories of age or body mass index. Plus-minus values are means of log-transformed apnea-hypopnea index \pm SEM. Geometric mean ratio is the ratio of the geometric mean of the apnea-hypopnea index among users of replacement hormones to the geometric mean among nonusers.

TABLE 2. Adjusted Odds Ratios for Prevalent Sleep-Disordered Breathing, Comparing Users of Replacement Hormones with Nonusers*

CHARACTERISTIC	NO. OF CASES/ NO. OF USERS	NO. OF CASES/ NO. OF NONUSERS	ADJUSTED ODDS RATIO	95% CONFIDENCE INTERVAL
ALL WOMEN	61/907	286/1945	0.55	0.41 - 0.75
ONLY CAUCASIANS	53/775	200/1436	0.64	0.46 - 0.90
AGE \geq 55 years	57/755	261/1723	0.59	0.43 - 0.82
AGE GROUP (Years)				
50-59	22/430	72/498	0.36	0.21 - 0.60
60-69	18/292	83/593	0.55	0.32 - 0.95
\geq 70	21/185	131/854	0.86	0.52 - 1.43
BODY-MASS INDEX (kg/m ²)				
< 25	12/292	46/530	0.59	0.30 - 1.14
25-30	15/345	62/696	0.60	0.33 - 1.08
> 30	34/270	178/719	0.52	0.34 - 0.79
TYPE OF HORMONE				
Estrogen only	38/525	286/1945	0.53	0.36 - 0.76
Estrogen and Progesterone	23/382	286/1945	0.60	0.38 - 0.96

* Sleep-disordered breathing was defined as an apnea-hypopnea index ≥ 15 . Estimates were derived from logistic regression models that included age, body mass index, waist-to-hip ratio, neck circumference, and race (except for a model for Caucasians alone) as covariates. To minimize residual confounding, age (continuous) and body mass index (continuous) were also included in models that examined the relation of hormone-replacement therapy to sleep-disordered breathing within categories of age or body mass index

TABLE 3. Adjusted Odds Ratios for Two Indices of Hypoxemia During Sleep, Comparing Users of Replacement Hormones with Nonusers*

CHARACTERISTIC	OXYHEMOGLOBIN SATURATION < 90% DURING 5% OR MORE OF SLEEP TIME (N=359)		OXYHEMOGLOBIN SATURATION < 90% DURING 10% OR MORE OF SLEEP TIME (N=198)	
	ADJUSTED ODDS RATIO	95% CONFIDENCE INTERVAL	ADJUSTED ODDS RATIO	95% CONFIDENCE INTERVAL
ALL WOMEN	0.74	0.55 - 0.99	0.63	0.43 - 0.94
ONLY CAUCASIANS	0.81	0.59 - 1.12	0.67	0.43 - 1.03
AGE ≥ 55 years	0.75	0.55 - 1.02	0.66	0.44 - 0.99
AGE GROUP (Years)				
50-59	0.59	0.35 - 0.99	0.41	0.19 - 0.89
60-69	0.59	0.35 - 1.01	0.44	0.21 - 0.92
≥ 70	1.03	0.66 - 1.63	1.09	0.62 - 1.91
BODY-MASS INDEX (kg/m ²)				
< 25	0.85	0.46 - 1.55	0.99	0.48 - 2.05
25-30	0.59	0.32 - 1.08	0.83	0.39 - 1.79
> 30	0.77	0.52 - 1.14	0.44	0.25 - 0.79
TYPE OF HORMONE				
Estrogen only	0.79	0.56 - 1.10	0.75	0.48 - 1.15
Estrogen and Progesterone	0.64	0.40 - 1.03	0.41	0.19 - 0.85


* Estimates were derived from logistic regression models that included age, body mass index, waist-to-hip ratio, neck circumference, and race (except for a model for Caucasians alone) as covariates. To minimize residual confounding, age (continuous) and body mass index (continuous) were also included in models that examined the relation of hormone-replacement therapy to sleep-disordered breathing within categories of age or body mass index

TABLE 4. Relation of Hormone-Replacement Therapy to Sleep Architecture*

	USERS Adjusted Mean (95% CI)	NONUSERS Adjusted Mean (95% CI)	P-VALUE	MODEL R ²
Stage 1 (% sleep time)	4.2 (4.0 - 4.4)	3.9 (3.8 - 4.1)	0.05	0.02
Stage 2 (% sleep time)	54.8 (54.0 - 55.5)	53.1 (52.5 - 53.6)	0.0005	0.05
Stage 3-4 (% sleep time)	18.6 (17.8 - 19.5)	21.1 (20.5 - 21.7)	<0.0001	0.07
REM (% sleep time)	20.2 (19.7 - 20.6)	19.7 (19.4 - 20.0)	0.07	0.03

* Adjusted estimates, 95% confidence intervals, and P-values (two-sided tests) were derived from linear regression of percent of total sleep time in each stage on hormone-replacement therapy status, age, race, body-mass index, and smoking status. The proportion of sleep time (P) in stages 1 and 3-4 was log-log transformed according to the formula: $-\log(-\log(P+0.001))$. Reported percentages were computed by back-transformation.

FIGURE 1



Online Data Supplement
Hormone-Replacement Therapy and Sleep-Disordered Breathing

Eyal Shahar, M.D., M.P.H.¹
Susan Redline, M.D., M.P.H.²
Terry Young, Ph.D.³
Lori L. Boland, M.P.H.¹
Carol M. Baldwin, RN, Ph.D.⁴
F. Javier Nieto, M.D., Ph.D.³
George T. O'Connor, M.D., M.S.⁵
David M. Rapoport, M.D.⁶
John A. Robbins, M.D.⁷

for the Sleep Heart Health Study Research Group

¹Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, MN

²Division of Clinical Epidemiology, Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, OH

³Department of Population Health Sciences, University of Wisconsin Medical School, Madison, WI

⁴Department of Medicine, Arizona Respiratory Center, University of Arizona Health Sciences Center, Tucson, AZ

⁵Department of Medicine, Boston University School of Medicine, Boston, MA

⁶Department of Medicine, New York University, New York, NY

⁷Department of Medicine, University of California at Davis, Sacramento, CA

Corresponding Author:

Eyal Shahar, M.D.

Division of Epidemiology

University of Minnesota

1300 South Second Street, Suite 300

Minneapolis, MN 55454

Phone: (612) 624-8231

Fax: (612) 624-0315

E-mail: shahar@epi.umn.edu

TABLE E1. Relation of Hormone Use to Selected Characteristics and Sleep-Related Variables*

	USERS (n = 907)				NONUSERS (n = 1945)			
	Mean \pm SD or %	25th %ile	50th %ile	75th %ile	Mean \pm SD or %	25th %ile	50th %ile	75th %ile
Age (yrs)	62 \pm 8	56	60	67	67 \pm 10	59	68	75
Race (%)								
Caucasian	85				74			
African-American	3				10			
American-Indian	8				14			
Other	3				3			
Body-mass index (kg/m ²)	27.8 \pm 5.4	23.9	27.0	30.8	28.9 \pm 6.0	24.7	28.0	32.2
Waist-to-hip ratio	0.87 \pm 0.09	0.81	0.88	0.94	0.9 \pm 0.09	0.84	0.91	0.97
Neck circumference (cm)	34.9 \pm 3.0	33.0	34.5	36.5	35.7 \pm 3.2	33.5	35.5	37.5
Reported General Health (%)								
Excellent/Very Good	41				32			
Good	28				30			
Fair/Poor	6				12			
Unknown	25				26			
"Excessively sleepy during the day" (%)								
Often/Almost always	16				11			
Never/Rarely/Sometimes	83				87			
Unknown	1				1			
"Do not get enough sleep" (%)								
Often/Almost always	20				19			
Never/Rarely/Sometimes	79				80			
Unknown	1				1			
"Wake up during the night" (%)								
Often/Almost always	25				25			
Never/Rarely/Sometimes	74				74			
Unknown	1				1			

TABLE E1. (Continued)

	USERS (n = 907)				NONUSERS (n = 1945)			
	mean \pm SD or %	25th %ile	50th %ile	75th %ile	Mean \pm SD or %	25th %ile	50th %ile	75th %ile
"Taking medication to help sleep" (%)								
Often/Almost always	13				8			
Never/Rarely/Sometimes	86				91			
Unknown	1				1			
Epworth Sleepiness Scale Score	7.5 \pm 4.3	4.0	7.0	10.0	7.1 \pm 4.2	4.0	6.0	10.0
Snoring Status (%)								
Habitual snorer	13				14			
Frequent snorer	12				9			
Light snorer	30				22			
Non-snorer	11				14			
Unknown	33				41			
Apnea-Hypopnea Index	4.5 \pm 6.9	0.6	1.9	5.4	7.9 \pm 11.7	1.3	4.0	9.7
% sleep time SaO ₂ < 90%	1.8 \pm 7.2	0.0	0.04	0.5	3.3 \pm 9.4	0.0	0.2	1.9

* Percentages might not add up to 100 because of rounding

TABLE E2. Relation of Hormone-Replacement Therapy to the Apnea- Hypopnea Index*

CHARACTERISTIC		N	ADJUSTED LOG (APNEA-HYPOPNEA INDEX)	ADJUSTED GEOMETRIC MEAN	ADJUSTED GEOMETRIC MEAN RATIO	95% CONFIDENCE INTERVAL
ALL WOMEN						
	Users	907	0.83 ± 0.04	2.3	0.73	0.65 - 0.81
	Nonusers	1945	1.15 ± 0.03	3.2		
RACE						
Caucasian	Users	775	0.88 ± 0.05	2.4	0.75	0.67 - 0.85
	Nonusers	1436	1.17 ± 0.03	3.2		
African-American	Users	30	0.40 ± 0.24	1.5	0.65	0.39 - 1.06
	Nonusers	187	0.84 ± 0.10	2.3		
American Indian	Users	75	0.83 ± 0.15	2.3	0.69	0.50 - 0.97
	Nonusers	266	1.20 ± 0.08	3.3		
Other	Users	27	0.38 ± 0.25	1.5	0.37	0.21 - 0.68
	Nonusers	56	1.36 ± 0.17	3.9		
AGE ≥ 55 years						
	Users	755	0.88 ± 0.05	2.4	0.70	0.62 - 0.79
	Nonusers	1723	1.23 ± 0.03	3.4		
AGE GROUP (Years)						
50-59	Users	430	0.85 ± 0.09	2.3	0.66	0.55 - 0.78
	Nonusers	498	1.27 ± 0.09	3.5		
60-69	Users	292	0.88 ± 0.08	2.4	0.71	0.59 - 0.85
	Nonusers	593	1.23 ± 0.05	3.4		
≥ 70	Users	185	0.86 ± 0.12	2.4	0.87	0.70 - 1.06
	Nonusers	854	1.00 ± 0.09	2.7		

TABLE E2. (Continued)

BODY-MASS INDEX (kg/m²)

< 25	Users	292	0.81 ± 0.09	2.2	0.76	0.63 - 0.91
	Nonusers	530	1.09 ± 0.08	3.0		
25-30	Users	345	0.76 ± 0.07	2.1	0.73	0.61 - 0.86
	Nonusers	696	1.08 ± 0.05	3.0		
> 30	Users	270	0.92 ± 0.09	2.5	0.70	0.58 - 0.84
	Nonusers	719	1.28 ± 0.07	3.6		

REPORTED GENERAL HEALTH

Excellent/Very Good	Users	373	0.80 ± 0.07	2.2	0.72	0.61 - 0.85
	Nonusers	627	1.13 ± 0.05	3.1		
Good	Users	253	0.84 ± 0.08	2.3	0.75	0.62 - 0.91
	Nonusers	584	1.13 ± 0.06	3.1		
Fair/Poor	Users	57	0.97 ± 0.17	2.6	0.84	0.58 - 1.23
	Nonusers	238	1.13 ± 0.09	3.1		
Unknown	Users	224	0.84 ± 0.09	2.3	0.68	0.55 - 0.84
	Nonusers	496	1.22 ± 0.07	3.4		

FREE OF MAJOR CLINICAL CONDITIONS⁺

Users	624	0.74 ± 0.05	2.1	0.73	0.64 - 0.83
Nonusers	1166	1.05 ± 0.04	2.9		

TYPE OF HORMONE

Estrogen only	Users	525	0.81 ± 0.06	2.3	0.71	0.63 - 0.81
	Nonusers	1945	1.15 ± 0.03	3.2		
Estrogen and Progesterone	Users	382	0.86 ± 0.07	2.4	0.75	0.64 - 0.87
	Nonusers	1945	1.15 ± 0.03	3.2		

* Estimates were derived from linear regression models that included age, body mass index, waist-to-hip ratio, neck circumference, and race group as covariates. All covariates, except race group, were entered as continuous variables. To minimize residual confounding, age (continuous) and body mass index (continuous) were also included in models that examined the relation of hormone-replacement therapy to sleep-disordered breathing within categories of age or body mass index. Plus-minus values are means of log-transformed apnea-hypopnea index \pm SEM. Geometric mean ratio is the ratio of the geometric mean of the apnea-hypopnea index among users of replacement hormones to the geometric mean among nonusers.

+Angina, myocardial infarction, revascularization procedure, heart failure, stroke, chronic bronchitis, emphysema, asthma, and diabetes

TABLE E3. Adjusted Odds Ratios for Prevalent Sleep-Disordered Breathing,
Comparing Users of Replacement Hormones with Nonusers*

CHARACTERISTIC	NO. OF CASES/ NO. OF USERS	NO. OF CASES/ NO. OF NONUSERS	ADJUSTED ODDS RATIO	95% CONFIDENCE INTERVAL
ALL WOMEN	61/907	286/1945	0.55	0.41 - 0.75
ONLY CAUCASIANS	53/775	200/1436	0.64	0.46 - 0.90
AGE \geq 55 years	57/755	261/1723	0.59	0.43 - 0.82
AGE GROUP (Years)				
50-59	22/430	72/498	0.36	0.21 - 0.60
60-69	18/292	83/593	0.55	0.32 - 0.95
\geq 70	21/185	131/854	0.86	0.52 - 1.43
BODY-MASS INDEX (kg/m ²)				
< 25	12/292	46/530	0.59	0.30 - 1.14
25-30	15/345	62/696	0.60	0.33 - 1.08
> 30	34/270	178/719	0.52	0.34 - 0.79
REPORTED GENERAL HEALTH				
Excellent/Very Good	21/373	78/627	0.61	0.36 - 1.03
Good	18/253	83/584	0.61	0.35 - 1.06
Fair/Poor	6/57	37/238	0.68	0.26 - 1.78
Unknown	16/224	88/496	0.42	0.23 - 0.75
FREE OF MAJOR CLINICAL CONDITIONS ⁺	41/624	152/1166	0.65	0.44 - 0.96

TABLE E3. (Continued)

TYPE OF HORMONE				
Estrogen only	38/525	286/1945	0.53	0.36 - 0.76
Estrogen and Progesterone	23/382	286/1945	0.60	0.38 - 0.96

* Sleep-disordered breathing was defined as an apnea-hypopnea index ≥ 15 . Estimates were derived from logistic regression models that included age, body mass index, waist-to-hip ratio, neck circumference, and race (except for a model for caucasians alone) as covariates. To minimize residual confounding, age (continuous) and body mass index (continuous) were also included in models that examined the relation of hormone-replacement therapy to sleep-disordered breathing within categories of age or body mass index

+Angina, myocardial infarction, revascularization procedure, heart failure, stroke, chronic bronchitis, emphysema, asthma, and diabetes